Pappas Ventures established Lumena in 2011 in order to address liver diseases characterized by impaired bile flow and retention of bile in the liver and the body – diseases that can lead to progressive liver damage and intractable itching. The company’s lead candidate, LUM-001, is specifically designed to have limited systemic exposure and targets the Apical Sodium-dependent Bile Acid Transporter (ASBT), which is localized on the luminal surface of the lower portion of the small intestines. LUM-001 works by preventing recycling of bile acids, thereby reducing bile acid accumulation, improving liver function and potentially relieving the extreme itching associated with cholestatic diseases.
Mike Grey, a Venture Partner with Pappas Ventures, is the President and Chief Executive Officer of Lumena. The company was acquired by Shire plc in June 2014.
San Diego, CA
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.